SEARCH

SEARCH BY CITATION

References

  • Adesanya CO, Yousuf KA, Co C, Gaur S, Ahmed S, Pothoulakis A et al. (2008). Is wider worse? QRS duration predicts cardiac mortality in patients with right bundle branch block. Ann Noninvasive Electrocardiol 13: 165170. DOI: 10.1111/j.1542-474X.2008.00216.x.
  • Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1S254.
  • Anonymous (2000). ICH S7A safety pharmacology studies for human pharmaceuticals. London, 16 November 2000. CPMP/ICH/539/00. ICH S7B. CPMP/ICH/539/00.
  • Anonymous (2005a). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14. CHMP/ICH/2/04.
  • Anonymous (2005b). The nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. ICH S7B. CHMP/ICH/423/02.
  • Breidthardt T, Christ M, Matti M, Schrafl D, Laule K, Noveanu M et al. (2007). QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure. Heart 93: 10931097. DOI: 10.1136/hrt.2006.102319.
  • Chen MX, Helliwell RM, Clare JJ (2009). In vitro profiling against ion channels beyond hERG as an early indicator of cardiac risk. Curr Opin Mol Ther 11: 269281.
  • Cordes J, Lib C, Dugasa J, Austin-LaFrancea R, Lightbownc I, Engwalla M et al. (2009). Translation between in vitro inhibition of the cardiac Nav1.5 channel and pre-clinical and clinical QRS widening. J Pharmacol Toxicol Methods 60: 221.
  • Darpo B (2010). The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159: 4957. DOI: 10.1111/j.1476-5381.2009.00487.x.
  • Delk C, Holstege CP, Brady WJ (2007). Electrocardiographic abnormalities associated with poisoning. Am J Emerg Med 25: 672687.
  • Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R (2008). High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov 7: 358368. DOI: 10.1038/nrd2552.
  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. the cardiac arrhythmia suppression trial. N Engl J Med 324: 781788.
  • Freedman RA, Karagounis LA, Steinberg JS (1992). Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. J Am Coll Cardiol 20: 12131219.
  • Harmer AR, Abi-Gerges N, Easter A, Woods A, Lawrence CL, Small BG et al. (2008). Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. J Pharmacol Toxicol Methods 57: 3041. DOI: 10.1016/j.vascn.2007.09.002.
  • Horwich T, Lee SJ, Saxon L (2003). Usefulness of QRS prolongation in predicting risk of inducible monomorphic ventricular tachycardia in patients referred for electrophysiologic studies. Am J Cardiol 92: 804809.
  • Jensen HK, Nielsen-Kudsk F (1988). Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. Pharmacol Toxicol 62: 166171.
  • Kalahasti V, Nambi V, Martin DO, Lam CT, Yamada D, Wilkoff BL et al. (2003). QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. Am J Cardiol 92: 798803.
  • Kang J, Wang L, Chen XL, Triggle DJ, Rampe D (2001). Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 59: 122126.
  • Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F et al. (2003). Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Devel 6: 470480.
  • Madias JE (2008). Drug-induced QRS morphology and duration changes. Cardiol J 15: 505509.
  • Pollard CE, Valentin JP, Hammond TG (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol 154: 15381543. DOI: 10.1038/bjp.2008.203.
  • Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 1221. DOI: 10.1111/j.1476-5381.2009.00207.x.
  • Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 3245.
  • Schulz M, Schmoldt A (2003). Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58: 447474.
  • Schwartz M, Patel M, Kazzi Z, Morgan B (2008). Cardiotoxicity after massive amantadine overdose. J Med Toxicol 4: 173179.
  • Seger DL (2006). A critical reconsideration of the clinical effects and treatment recommendations for sodium channel blocking drug cardiotoxicity. Toxicol Rev 25: 283296.
  • Takanaka C, Lee JK, Nonokawa M, Sugiyama T, Yame S (1994). Frequency dependent effects of class I antiarrhythmic agents studied in patients with implanted pacemakers. Pacing Clin Electrophysiol 17: 21002105.
  • Tan HL, Bezzina CR, Smits JP, Verkerk AO, Wilde AA (2003). Genetic control of sodium channel function. Cardiovasc Res 57: 961973.
  • Thanacoody HK, Thomas SH (2005). Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 24: 205214.
  • Titier K, Canal M, Deridet E, Abouelfath A, Gromb S, Molimard M et al. (2004). Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 199: 5260.
  • Valentin JP (2010). Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol 159: 511. DOI: 10.1111/j.1476-5381.2009.00547.x.
  • Valentin JP, Hammond T (2008). Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 58: 7787. DOI: 10.1016/j.vascn.2008.05.007.
  • Valentin JP, Pollard C, Lainee P, Hammond T (2010). Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines. Br J Pharmacol 159: 2533. DOI: 10.1111/j.1476-5381.2009.00530.x.
  • Vaughan Williams EM (1991). Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. J Clin Pharmacol 31: 123135.
  • Webster R, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 5: 116126.
  • Wible BA, Kuryshev YA, Smith SS, Liu Z, Brown AM (2008). An ion channel library for drug discovery and safety screening on automated platforms. Assay Drug Dev Technol 6: 765780. DOI: 10.1089/adt.2008.0171.
  • Yatani A, Akaike N (1985). Blockage of the sodium current in isolated single cells from rat ventricle with mexiletine and disopyramide. J Mol Cell Cardiol 17: 467476.
  • Yoshida H, Furuta T (1999). Tissue penetration properties of macrolide antibiotics–comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats. Jpn J Antibiot 52: 497503.